Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The operating income for Nexien BioPharma, Inc. as of March 31, 2025 is -0.12 MM.
- The net income for Nexien BioPharma, Inc. as of March 31, 2025 is -0.19 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-03-31 | -0.12 | -0.19 | |
2024-12-31 | -0.12 | -0.21 | |
2024-09-30 | -0.11 | -0.20 | |
2024-06-30 | -0.16 | -0.24 | |
2024-03-31 | -0.16 | -0.25 | |
2023-12-31 | -0.21 | -0.27 | |
2023-09-30 | -0.27 | -0.34 | |
2023-06-30 | -0.28 | -0.36 | |
2023-03-31 | -0.29 | -0.37 | |
2022-12-31 | -0.38 | -0.47 | |
2022-09-30 | -0.52 | -0.60 | |
2022-06-30 | -0.56 | -0.63 | |
2022-03-31 | -0.67 | -0.71 | |
2021-12-31 | -0.28 | -0.31 | |
2021-09-30 | -0.90 | -0.92 | |
2021-06-30 | -1.84 | -1.86 | |
2021-03-31 | -2.34 | -2.35 | |
2020-12-31 | -3.12 | -3.12 | |
2020-09-30 | -2.99 | -2.99 | |
2020-06-30 | |||
2020-03-31 |
Income Statement: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-03-31 | ||
2024-12-31 | -0.00 | -0.00 |
2024-09-30 | -0.00 | -0.00 |
2024-06-30 | -0.00 | -0.00 |
2024-03-31 | -0.00 | -0.00 |
2023-12-31 | -0.00 | -0.00 |
2023-09-30 | -0.01 | -0.01 |
2023-06-30 | -0.01 | |
2023-03-31 | -0.01 | -0.01 |
2022-12-31 | -0.01 | -0.01 |
2022-09-30 | -0.01 | -0.01 |
2022-06-30 | -0.01 | |
2022-03-31 | -0.01 | -0.01 |
2021-12-31 | -0.01 | -0.01 |
2021-09-30 | -0.02 | -0.02 |
2021-06-30 | -0.03 | |
2021-03-31 | -0.04 | -0.04 |
2020-12-31 | -0.06 | -0.06 |
2020-09-30 | -0.06 | -0.06 |
2020-06-30 | -0.05 | |
2020-03-31 | -0.06 | -0.06 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Nexien BioPharma, Inc. as of March 31, 2025 is -0.06 MM.
- The cash from financing activities for Nexien BioPharma, Inc. as of March 31, 2025 is 0.06 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-03-31 | -0.06 | 0.06 | |
2024-12-31 | -0.07 | 0.07 | |
2024-09-30 | -0.06 | 0.04 | |
2024-06-30 | -0.06 | 0.03 | |
2024-03-31 | -0.07 | 0.03 | |
2023-12-31 | -0.07 | ||
2023-09-30 | -0.08 | ||
2023-06-30 | -0.08 | ||
2023-03-31 | -0.09 | 0.00 | |
2022-12-31 | -0.09 | -0.01 | 0.17 |
2022-09-30 | -0.08 | 0.17 | |
2022-06-30 | -0.08 | 0.17 | |
2022-03-31 | -0.08 | 0.19 | |
2021-12-31 | -0.08 | 0.01 | 0.02 |
2021-09-30 | -0.09 | 0.09 | |
2021-06-30 | -0.09 | 0.10 | |
2021-03-31 | -0.08 | 0.09 | |
2020-12-31 | -0.09 | 0.09 | |
2020-09-30 | -0.09 | 0.03 | |
2020-06-30 | |||
2020-03-31 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- The p/e for Nexien BioPharma, Inc. as of March 31, 2025 is -9.38.
- The p/book for Nexien BioPharma, Inc. as of March 31, 2025 is -4.69.
- The p/tbv for Nexien BioPharma, Inc. as of March 31, 2025 is -4.69.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-03-31 | -9.38 | -4.69 | -4.69 |
2024-12-31 | -5.06 | -5.06 | |
2024-09-30 | -8.02 | -6.07 | -6.07 |
2024-06-30 | -8.02 | -6.07 | -6.07 |
2024-03-31 | -4.37 | -4.37 | |
2023-12-31 | -4.87 | -5.72 | |
2023-09-30 | -11.35 | -16.30 | -16.30 |
2023-06-30 | -5.65 | -8.96 | -8.96 |
2023-03-31 | -6.64 | -15.51 | |
2022-12-31 | -19.31 | -19.31 | |
2022-09-30 | -34.39 | -34.39 | |
2022-06-30 | 0.00 | 0.00 | |
2022-03-31 | -7.69 | -38.46 | -38.46 |
2021-12-31 | -4.63 | -106.49 | -106.49 |
2021-09-30 | -1.86 | 210.35 | 210.35 |
2021-06-30 | |||
2021-03-31 | -1.48 | 167.15 | 167.15 |
2020-12-31 | -1.16 | 153.06 | 153.06 |
2020-09-30 | -1.21 | -484.73 | -484.73 |
2020-06-30 | -1.31 | -551.29 | -551.29 |
2020-03-31 | -1.15 | 37.03 | 37.03 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
- The ebit/ev for Nexien BioPharma, Inc. as of March 31, 2025 is -0.09.
- The ebit (3y)/ev for Nexien BioPharma, Inc. as of March 31, 2025 is -0.12.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-03-31 | -0.09 | -0.12 |
2024-12-31 | -0.09 | -0.14 |
2024-09-30 | -0.11 | -0.18 |
2024-06-30 | -0.11 | -0.20 |
2024-03-31 | -0.17 | -0.21 |
2023-12-31 | -0.18 | -0.32 |
2023-09-30 | -0.08 | -0.22 |
2023-06-30 | -0.16 | -0.42 |
2023-03-31 | -0.14 | -0.35 |
2022-12-31 | -0.19 | -0.46 |
2022-09-30 | -0.15 | -0.36 |
2022-06-30 | -13.18 | -32.38 |
2022-03-31 | -0.13 | -0.78 |
2021-12-31 | -0.22 | -0.55 |
2021-09-30 | -0.54 | -0.73 |
2021-06-30 | ||
2021-03-31 | -0.68 | -0.86 |
2020-12-31 | -0.86 | -0.86 |
2020-09-30 | -0.82 | -0.81 |
2020-06-30 | -0.76 | -0.78 |
2020-03-31 | -0.88 | -0.79 |
Management Effectiveness
- The roa for Nexien BioPharma, Inc. as of March 31, 2025 is -14.80.
Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
2025-03-31 | -14.80 | ||||
2024-12-31 | -74.91 | ||||
2024-09-30 | -11.16 | ||||
2024-06-30 | -4.23 | ||||
2024-03-31 | -3.55 | ||||
2023-12-31 | -3.26 | ||||
2023-09-30 | -2.91 | -18.57 | -4.20 | -4.20 | |
2023-06-30 | -2.93 | -25.70 | -5.81 | -5.81 | |
2023-03-31 | -3.28 | -13.19 | -3.10 | -3.10 | |
2022-12-31 | -80.54 | -7.56 | 1.23 | -0.97 | |
2022-09-30 | -84.14 | -9.81 | 1.59 | -1.25 | |
2022-06-30 | -27.84 | -8.18 | 1.29 | -0.98 | |
2022-03-31 | -9.31 | -15.01 | |||
2021-12-31 | -17.00 | -13.15 | |||
2021-09-30 | -53.50 | -2.87 | |||
2021-06-30 | -81.63 | -277.40 | 1.08 | -13.53 | |
2021-03-31 | -20.09 | -24.82 | -82.96 | 0.30 | -2.87 |
2020-12-31 | -21.27 | -24.33 | -49.24 | -0.01 | -1.43 |
2020-09-30 | -14.53 | -16.30 | -661.75 | -13.85 | -19.38 |
2020-06-30 | -8.60 | -10.05 | -474.11 | -24.06 | -26.19 |
2020-03-31 | -4.04 | -4.08 | -32.27 | -2.25 | -2.25 |
Gross Margins
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 | |||
2020-06-30 | |||
2020-03-31 |
Identifiers and Descriptors
Central Index Key (CIK) | 1625288 |
Industry Groups
SIC 2834 - Pharmaceutical Preparations |